A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma

NCT07632235 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

112

Enrollment

OTHER

Sponsor class

Conditions

Intrahepatic Cholangiocarcinoma (Icc)

Interventions

DRUG: Celecoxib + Pembrolizumab + Gemcitabine/Cisplatin
DRUG: Pembrolizumab + Gemcitabine/Cisplatin

Sponsor

Shanghai 6th People's Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]